chronic lymphocytic leukemia

E822402

Chronic lymphocytic leukemia is a slow-growing cancer of the blood and bone marrow characterized by an overproduction of abnormal lymphocytes, most commonly affecting older adults.

All labels observed (4)

Label Occurrences
chronic lymphocytic leukemia canonical 9
small lymphocytic lymphoma 3
B-cell leukemia 1

How this entity was disambiguated

Statements (64)

Predicate Object
instanceOf hematologic malignancy ⓘ
leukemia ⓘ
lymphoproliferative disorder ⓘ
non-Hodgkin lymphoma ⓘ
affectsCellType B lymphocyte ⓘ
linked to: B lymphocytes
affectsSystem blood ⓘ
bone marrow ⓘ
associatedWithGeneMutation NOTCH1 mutation ⓘ
SF3B1 mutation ⓘ
TP53 mutation ⓘ
associatedWithGeneticAbnormality del(11q) ⓘ
del(13q14) ⓘ
del(17p) ⓘ
trisomy 12 ⓘ
canBe asymptomatic at diagnosis ⓘ
canTransformTo diffuse large B-cell lymphoma ⓘ
commonLaboratoryFinding absolute lymphocytosis ⓘ
anemia ⓘ
thrombocytopenia ⓘ
commonSign hepatomegaly ⓘ
lymphadenopathy ⓘ
splenomegaly ⓘ
commonSymptom fatigue ⓘ
night sweats ⓘ
recurrent infections ⓘ
unintentional weight loss ⓘ
complication autoimmune hemolytic anemia ⓘ
hypogammaglobulinemia ⓘ
immune thrombocytopenia ⓘ
increased infection risk ⓘ
diagnosedBy complete blood count ⓘ
flow cytometry immunophenotyping ⓘ
peripheral blood smear ⓘ
epidemiologyRegion most common leukemia in Western countries ⓘ
hasAbbreviation CLL ⓘ
hasFullName chronic lymphocytic leukemia ⓘ
hasICD10Code C91.1 ⓘ
hasImmunophenotypeMarker CD19 ⓘ
CD20 dim ⓘ
CD23 ⓘ
CD5-positive B cells ⓘ
surface immunoglobulin dim ⓘ
hasPrognosticMarker IGHV mutation status ⓘ
TP53 disruption ⓘ
beta-2 microglobulin level ⓘ
isCharacterizedBy accumulation of monoclonal B cells ⓘ
bone marrow infiltration ⓘ
lymph node enlargement ⓘ
lymphocytosis ⓘ
slow progression ⓘ
mayRequire bone marrow biopsy ⓘ
primaryTreatmentOption watchful waiting ⓘ
riskFactor advanced age ⓘ
family history of CLL ⓘ
sexPredominance more common in males ⓘ
transformationSyndromeName Richter transformation ⓘ
treatmentOption BCL2 inhibitor ⓘ
Bruton tyrosine kinase inhibitor ⓘ
allogeneic stem cell transplantation ⓘ
anti-CD20 monoclonal antibody ⓘ
chemoimmunotherapy ⓘ
typicalCourse indolent ⓘ
typicalOnsetAge >=60 years ⓘ
typicalOnsetAgeGroup older adults ⓘ

How these facts were elicited

Referenced by (14)

Full triples — surface form annotated when it differs from this entity's canonical label.

MabThera → indication → chronic lymphocytic leukemia ⓘ
Bruton tyrosine kinase → associatedWithDisease → chronic lymphocytic leukemia ⓘ
Ruxience → isUsedForTreatmentOf → chronic lymphocytic leukemia ⓘ
Riabni → hasIndication → chronic lymphocytic leukemia ⓘ
BTK → associatedWithDisease → chronic lymphocytic leukemia ⓘ
Venclexta → indication → small lymphocytic lymphoma ⓘ
linked to: chronic lymphocytic leukemia
chronic lymphocytic leukemia → hasAbbreviation → CLL ⓘ
linked to: chronic lymphocytic leukemia
acalabrutinib → indication → small lymphocytic lymphoma ⓘ
linked to: chronic lymphocytic leukemia
zanubrutinib → indication → chronic lymphocytic leukemia ⓘ
zanubrutinib → indication → small lymphocytic lymphoma ⓘ
linked to: chronic lymphocytic leukemia
MS4A1 → associatedWithDisease → chronic lymphocytic leukemia ⓘ
subject linked to: MS4A1 gene
B1 antigen → associatedWithDisease → B-cell leukemia ⓘ
linked to: chronic lymphocytic leukemia
CD21 → associatedWithDisease → chronic lymphocytic leukemia ⓘ
CD22 → associatedWithDisease → chronic lymphocytic leukemia ⓘ